ReviewDiabetologia2022
Personalised prevention of type 2 diabetes.
Review in Diabetologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06513026 (Milk for Diabetes Prevention), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Milk for Diabetes Prevention
Who cites it
10 citing papers in PubMed.
- Effectiveness of a Family-based Health Promotion Intervention for Women With Prior GDM: The Face-It RCT.The Journal of clinical endocrinology and metabolism · 2025Trial
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.Nature metabolism · 2024Trial
- Advancing Precision Diagnosis of Sarcopenic Obesity Through Digital Technologies, Wearables and Omics Data.Life (Basel, Switzerland) · 2025Review
- Chronic hepatitis B with type 2 diabetes mellitus: Association between glycemic control and liver fibrosis.World journal of diabetes · 2025Article
- Use of technology in prediabetes and precision prevention.Journal of diabetes investigation · 2025Review
- Impact of individual and environmental factors on dietary or lifestyle interventions to prevent type 2 diabetes development: a systematic review.Communications medicine · 2023Article
- Multi-omics signatures in new-onset diabetes predict metabolic response to dietary inulin: findings from an observational study followed by an interventional trial.Nutrition & diabetes · 2023Observational
- A polygenic and family risk score are both independently associated with risk of type 2 diabetes in a population-based study.Scientific reports · 2023Article
- Type 2 Diabetes Prevention Programs-From Proof-of-Concept Trials to National Intervention and Beyond.Journal of clinical medicine · 2023Review
- Clinical effect of kyphoplasty in the treatment of osteoporotic thoracolumbar compression fractures in patients with diabetes.Frontiers in surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
It is well established from clinical trials that behavioural interventions can halve the risk of progression from prediabetes to type 2 diabetes but translating this evidence of efficacy into effective real-world interventions at scale is an ongoing challenge. A common suggestion is that future preventive interventions need to be more personalised in order to enhance effectiveness. This review evaluates the degree to which existing interventions are already personalised and outlines how greater personalisation could be achieved through better identification of those at high risk, division of type 2 diabetes into specific subgroups and, above all, more individualisation of the behavioural targets for preventive action. Approaches using more dynamic real-time data are in their scientific infancy. Although these approaches are promising they need longer-term evaluation against clinical outcomes. Whatever personalised preventive approaches for type 2 diabetes are developed in the future, they will need to be complementary to existing individual-level interventions that are being rolled out and that are demonstrably effective. They will also need to ideally synergise with, and at the very least not detract attention from, efforts to develop and implement strategies that impact on type 2 diabetes risk at the societal level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.